Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Acesion, Addendum, adware, affirmative, AI, anchored, ANCOVA, artificial, authentication, automated, bifurcation, Black, capture, CASL, CCPA, chosen, Circulation, clarification, clarified, Colorado, comment, concurred, conjunction, Connecticut, CPRA, credential, deceptive, deep, defense, dialogue, diligence, disaggregated, disaster, domain, email, embedded, encryption, expert, Extortion, facilitate, facilitated, fake, FASB, feature, Featured, Florida, forensic, gather, Gaza, hardware, harvesting, hosting, hourly, importantly, inconsistent, infer, inhibitor, inquiry, instrument, Interagency, IRS, ITT, Lancet, leaked, lieu, manual, marked, misrepresentative, monumental, nadir, necessitate, notified, notify, NS, offline, online, PA, path, percent, Pharma, Philadelphia, PIPEDA, PIPL, pretax, reconciling, reformat, reformatted, reiterated, resubmission, revealed, RTF, Science, sensitive, sensitivity, server, simultaneously, SIP, SK, sNDA, software, sterling, stuffing, supine, threat, Treasury, UK, undermine, undertaken, underwent, underwritten, unemployment, unfair, unstable, variance, vendor, Vice, Virginia, VP, VR, wiretapping, written
Financial report summary
?Competition
InCarda TherapeuticsManagement Discussion
- We recorded revenue of $1.0 million for the year ended December 31, 2023. This revenue was the result of having reached a milestone pursuant to our License and Collaboration Agreement, dated May 15, 2021, with Ji Xing Pharmaceuticals Limited, such party being referred to as Ji Xing and such agreement as the Ji Xing License Agreement, due upon the successful initiation of a Phase 1 Clinical Trial of a pharmaceutical product that uses a device to deliver etripamil by nasal spray by or on behalf of Ji Xing for the treatment of PSVT in the People’s Republic of China, or the Territory, including mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan.